Myeloid cannabinoid CB1 receptor deletion confers atheroprotection in male mice by reducing macrophage proliferation in a sex-dependent manner.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
05 Jun 2024
Historique:
received: 26 01 2024
revised: 21 03 2024
accepted: 01 05 2024
medline: 5 6 2024
pubmed: 5 6 2024
entrez: 5 6 2024
Statut: aheadofprint

Résumé

Although the cannabinoid CB1 receptor has been implicated in atherosclerosis, its cell-specific effects in this disease are not well understood. To address this, we generated a transgenic mouse model to study the role of myeloid CB1 signaling in atherosclerosis. Here, we report that male mice with myeloid-specific Cnr1 deficiency on atherogenic background developed smaller lesions and necrotic cores than controls, while only minor genotype differences were observed in females. Male Cnr1 deficient mice showed reduced arterial monocyte recruitment and macrophage proliferation with less inflammatory phenotype. The sex-specific differences in proliferation were dependent on estrogen receptor (ER)α-estradiol signaling. Kinase activity profiling identified a CB1-dependent regulation of p53 and cyclin-dependent kinases. Transcriptomic profiling further revealed chromatin modifications, mRNA processing and mitochondrial respiration among the key processes affected by CB1 signaling, which was supported by metabolic flux assays. Chronic administration of the peripherally-restricted CB1 antagonist JD5037 inhibited plaque progression and macrophage proliferation, but only in male mice. Finally, CNR1 expression was detectable in human carotid endarterectomy plaques and inversely correlated with proliferation, oxidative metabolism and inflammatory markers, suggesting a possible implication of CB1-dependent regulation in human pathophysiology. Impaired macrophage CB1 signaling is atheroprotective by limiting their arterial recruitment, proliferation and inflammatory reprogramming in male mice. The importance of macrophage CB1 signaling appears to be sex-dependent.

Identifiants

pubmed: 38838211
pii: 7688406
doi: 10.1093/cvr/cvae125
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Yong Wang (Y)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Guo Li (G)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Bingni Chen (B)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

George Shakir (G)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Mario Volz (M)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Emiel P C van der Vorst (EPC)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.
Institute for Molecular Cardiovascular Research (IMCAR), Aachen-Maastricht Institute for CardioRenal Disease (AMICARE) and Interdisciplinary Center for Clinical Research (IZKF), RWTH Aachen University, Aachen, Germany.

Sanne L Maas (SL)

Institute for Molecular Cardiovascular Research (IMCAR), Aachen-Maastricht Institute for CardioRenal Disease (AMICARE) and Interdisciplinary Center for Clinical Research (IZKF), RWTH Aachen University, Aachen, Germany.

Martina Geiger (M)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Carolin Jethwa (C)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Alexander Bartelt (A)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.
DZHK (German Center for Cardiovasular Research), partner site Munich Heart Alliance.
Institute for Diabetes and Cancer, Helmholtz Zentrum Munich, Neuherberg, Germany.
Department of Molecular Metabolism & Sabri Ülker Center for Metabolic Research, Harvard T.H. Chan School of Public Health, Boston, USA.

Zhaolong Li (Z)

Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar - Technical University Munich (TUM), Munich, Germany.

Justus Wettich (J)

Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar - Technical University Munich (TUM), Munich, Germany.

Nadja Sachs (N)

Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar - Technical University Munich (TUM), Munich, Germany.

Lars Maegdefessel (L)

DZHK (German Center for Cardiovasular Research), partner site Munich Heart Alliance.
Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar - Technical University Munich (TUM), Munich, Germany.

Maliheh Nazari Jahantigh (M)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Michael Hristov (M)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Michael Lacy (M)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Beat Lutz (B)

Institute of Physiological Chemistry, University Medical Center, Mainz, Germany.

Christian Weber (C)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.
DZHK (German Center for Cardiovasular Research), partner site Munich Heart Alliance.
Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, 6229 ER Maastricht, The Netherlands.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Stephan Herzig (S)

DZHK (German Center for Cardiovasular Research), partner site Munich Heart Alliance.
Institute for Diabetes and Cancer, Helmholtz Zentrum Munich, Neuherberg, Germany.
Chair Molecular Metabolic Control, TU Munich.
Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.

Raquel Guillamat Prats (R)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.

Sabine Steffens (S)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität Munich, Germany.
DZHK (German Center for Cardiovasular Research), partner site Munich Heart Alliance.

Classifications MeSH